⌕
Ionis Pharmaceuticals · IONS · Nasdaq
Tenet 27 · Weak
Compare
$28.01−3.61%At closeTenet 27 · Weak
$28.01−1.05 (−3.61%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Ionis Pharmaceuticals (IONS) Institutional Ownership

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice

5 figures withheld by our checks. Each blank figure names its reason.

13F fund flowQuarter ended Jun 30, 2026. Withheld: many filers have already reported a later quarter, so their changes in this quarter are not on file and the counts of new, added, trimmed and closed positions are not shown. These positions are 140 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
SHARES HELD BY 13F FILERS
withheld
withheld by our checks · 526 filers, Jun 30, 2026
# 13F FUNDS
526
13F VALUE
$14.8B
187.1M shares
Not reported in the company's filings for this period.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Nov 10, 2026Hayden Michael RdirectorAcquired · Open-market buy5,000$29.64↗
Oct 16, 2026Devers Shannon L.EVP, Chief Human Resources OfcDisposed · Open-market sale1,357$43.54↗
Oct 16, 2026Swayze EricEVP ResearchDisposed · Open-market sale53$43.54↗
Oct 15, 2026Devers Shannon L.EVP, Chief Human Resources OfcAcquired · Option exercise2,820—↗
Oct 15, 2026Devers Shannon L.EVP, Chief Human Resources OfcDisposed · Option exercise2,820Restricted Stock Unit—↗
Oct 15, 2026Swayze EricEVP ResearchAcquired · Option exercise125—↗
Oct 15, 2026Swayze EricEVP ResearchDisposed · Option exercise125Restricted Stock Unit—↗
Aug 31, 2026BENNETT C FRANKEVP, Chief Scientific OfficerAcquired · Other110$51.31↗
Aug 31, 2026O'NEIL PATRICK R.EVP CLO & General CounselAcquired · Other63$51.31↗
Aug 31, 2026Monia Brett PChief Executive OfficerAcquired · Other98$51.31↗
Aug 31, 2026Birchler BrianEVP, Corp and Development OpsAcquired · Other58$51.31↗
Jul 31, 2026Hayden Michael RdirectorAcquired · Open-market buy5,000$51.60↗
Jul 30, 2026Hayden Michael RdirectorAcquired · Open-market buy15,000$53.38↗
Jul 15, 2026Reikes Peter NdirectorAcquired · Grant / award3,399Restricted Stock Unit—↗
Jul 15, 2026HANTSON LUDWIGdirectorAcquired · Grant / award3,399Restricted Stock Unit—↗
Jul 15, 2026HERMAN JOAN EdirectorAcquired · Option exercise5,220—↗
Jul 15, 2026HERMAN JOAN EdirectorDisposed · Option exercise5,220Restricted Stock Unit—↗
Jul 15, 2026BERTHELSEN SPENCER RdirectorAcquired · Option exercise5,220—↗
Jul 15, 2026BERTHELSEN SPENCER RdirectorDisposed · Option exercise5,220Restricted Stock Unit—↗
Jul 7, 2026BENNETT C FRANKEVP, Chief Scientific OfficerDisposed · Open-market sale5,536$83.58↗

* Holdings as reported for Jun 30, 2026, 140 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How many 13F filers hold Ionis Pharmaceuticals?

Ionis Pharmaceuticals was held by 526 13F filers as of Jun 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.